N/A
Completed N=71
Serum Levels of C Type Natriuretic Peptide in Different Reproductive Periods
Serum CNP Levels · Healthy Reproductive Age Women · Healthy Perimenopausal Women · Healthy Postmenopausal Women
Source: ClinicalTrials.gov NCT04000815 ↗
Enrolled (actual)
71
Serious AEs
—
Results posted
Mar 2020
Primary outcomePrimary: Serum C Type Natriuretic Peptide Levels — 43.68; 55.98; 116.36 pg/ml — p=<0.017
Summary
Recent studies have shown that C natriuretic peptide (CNP) is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors.It has been suggested that the transport of cGMP to oocyte via gap junctions causes a continuous increase in cyclic adenosine monophosphate (cAMP) levels within the oocyte. An important role of increased cAMP levels in oocyte is shown to suppress meiotic progression. Deoxyribonucleic acid (DNA) studies in animals have shown that expression of the natriuretic peptide precursor increases during the periovulatory period and shows that this increase decreases rapidly after Luteinizing hormone(LH) / human chorionic(hCG) stimulation. Human studies have shown that after ovulation induction, the CNP level in follicular fluid decreases following ovulatory dose of hCG (9).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum C Type Natriuretic Peptide Levels |
43.68; 55.98; 116.36 | <0.017 sig |
| SECONDARY Correlation Between Serum CNP and Follicle Stimulating Hormone and Luteinizing Hormone Levels in Groups 1 and 2 |
5.28; 13.12; 5.71; 5.16 | <0.05 sig |
| SECONDARY Correlation Between Serum CNP and Antral Follicle Count (AFC) in Groups 1 and 2 |
14.2; 8.33 | <0.05 sig |
| SECONDARY Correlation Between Serum CNP and Estradiol Levels in Groups 1 and 2 |
41; 22 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Healthy
- Regular cyclic menstruation for reproductive age group
Exclusion Criteria
- No systemic disease(cardiac, renal...etc)
- Smoking
- Drug usage
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT04000815). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.